Solara Q2 FY27: Revenue up 33% to INR 4178 Mn, EBITDA doubles, best quarter in 5 years
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts more than Nifty Microcap 250 and 9.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Q2 FY27 revenue grew 33% year-on-year to INR 4,178 million, with EBITDA more than doubling to INR 769 million - their best quarter in five years. PAT swung to INR 285 million from a loss of INR 101 million, EPS at INR 5.92. Base business revenue grew 37% with EBITDA margin up 440 basis points to 23.6%. Ibuprofen is near breakeven. Net debt fell 19% to INR 5,000 million, net debt to EBITDA improved to 1.8 times from 3.2 times.
Strong all-round results with revenue, profitability and balance sheet improvement. Likely positive for stock sentiment.